More Island Pharmaceuticals Ltd news
Island Pharmaceuticals LtdASX: ILA

ISLA-101 Phase 2b clinical trial enrols first subjects

Jan 7, 2025 at 9:48 PM EST · Issued by Island Pharmaceuticals Ltd

Filed with ASX · Jan 7, 2025 at 9:48 PM EST

On 6ix: 6ix.com/news/isla-101-phase-2b-clinical-trial-enrols-first-subjects

Island Pharmaceuticals Ltd has released a press release.

View Attachment

6ix hasn’t read this filing yet.

Island Pharmaceuticals Ltd on 6ix

Earlier from Island Pharmaceuticals

  • US patent granted for ISLA-101Dec 10, 2024
  • ISLA-101 shows anti-dengue activity in Phase 2a readoutNov 26, 2024
  • Receipt of R&D tax refund for FY2024Nov 21, 2024
  • Clinical trial progress updateNov 18, 2024
  • Island completes $3.5m PlacementOct 3, 2024

Later from Island Pharmaceuticals

  • Completion of enrolment in Phase 2b armJan 21, 2025
  • Completion of patient dosing in Phase 2b clinical trialFeb 11, 2025
  • Phase 2a/b clinical trial updateApr 22, 2025
  • Quarterly Activities & Cashflow ReportApr 29, 2025
  • Island completes $3.6 million placementMay 20, 2025
All Island Pharmaceuticals news releases↗

Follow Island Pharmaceuticals into a list and get an email when it puts out news.

Follow Island Pharmaceuticals
  • About 6ix
  • Editorial & Sourcing
  • Corrections
  • Contact
  • Privacy
  • Terms
  • Disclaimer